Stanford researchers have developed a new apparatus for analyzing spatially partially coherent light, enabling future applications in optical communications system and environmental sensing.
A research team led by Dr. Hoon Ryu from the Korea Institute of Science and Technology (KIST) has uncovered a new mechanism involving astrocytes for treating Alzheimer’s disease (AD) and proposed a novel therapeutic target.
A team of researchers from NUS Institute for Health Innovation & Technology (iHealthtech), led by Associate Professor Shao Huilin and Associate Professor Brian Lim, has developed a first-of-its-kind technology to map out diverse protein interactions in cells using DNA barcodes.
The technology, dubbed TETRIS, can explicitly identify and quantify multiple interacting partners in large protein assemblies. By capturing the complex hierarchy of protein interactions within tumour cells, the technology uncovers detailed molecular mechanisms driving disease progression. This enables more precise diagnostics, allowing for the accurate sub-typing of cancers and the identification of aggressive forms of the disease in just a few hours, which was not possible previously.
A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
In addition to the studies featured on the press program (details here) for the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies were recommended by ASTRO experts and may be of interest to journalists.
This special edition features advances in radiation therapy approaches presented by MD Anderson researchers at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. Information on all MD Anderson ASTRO Annual Meeting content can be found at MDAnderson.org/ASTRO.
The annual meeting will feature 23 abstracts from UCLA investigators that highlight key areas of radiation oncology, including new research in subspecialties ranging from survivorship, lung cancer/thoracic malignancies, physics, sarcoma, gastrointestinal cancer, genitourinary cancer, gynecological cancer, pediatric cancer and diversity, equity and inclusion in healthcare.
Leading experts in radiation therapy from Penn Medicine’s Abramson Cancer Center and the Perelman School of Medicine will present new results from clinical trials and research studies at the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting.
Irvine, Calif., Sept. 27, 2024 — Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body’s internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function. This discovery offers new avenues for prevention and treatment strategies.